Publications by authors named "Spalmai Hemat"
Multiple Sclerosis Disease Activity and Disability Following Cessation of Fingolimod for Pregnancy.
Neurol Neuroimmunol Neuroinflamm
July 2023
Article Synopsis
- Discontinuing fingolimod two months before pregnancy is advised to reduce risks for fetal harm, but the impact on pregnancy-related MS relapses is still unclear.
- A study involving 213 pregnancies tracked relapse rates in women who stopped fingolimod before or during pregnancy, revealing high incidence rates of relapses both during pregnancy and postpartum.
- Approximately 6% of women experienced significant disability due to severe relapses after stopping fingolimod, with most relapses occurring within the first three months after giving birth.